Fig. 2.
Kaplan-Meier curve analyses of 100 patients with anal squamous cell carcinoma, who received for primary treatment either surgery, concurrent chemoradiotherapy (CRT), or concurrent chemoradiotherapy plus immunotherapy (CRT-I), from April 2012 through May 2023. Curves show rates of (A) overall survival, (B) progression-free survival, (C) distant metastasis-free survival, and (D) locoregional relapse-free survival.